Elena Torre

Ancona, 60126, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real-world evidence.

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real-world evidence.

Journal: British journal of haematology

Published: June 15, 2026

Rapid and durable recovery of immune effector cells in myelofibrosis patients treated with momelotinib.

Rapid and durable recovery of immune effector cells in myelofibrosis patients treated with momelotinib.

Journal: Haematologica

Published: June 20, 2025

Emerging Therapeutic Approaches for Anemia in Myelofibrosis.

Emerging Therapeutic Approaches for Anemia in Myelofibrosis.

Journal: Current hematologic malignancy reports

Published: March 31, 2025

Clinical utility of investigations in triple-negative thrombocytosis: A real-world, multicentre evaluation of UK practice.

Clinical utility of investigations in triple-negative thrombocytosis: A real-world, multicentre evaluation of UK practice.

Journal: British journal of haematology

Published: April 19, 2024

Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights.

Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights.

Journal: International journal of molecular sciences

Published: December 18, 2023

Epidemiology of cutaneous T-cell lymphomas: state of the art and a focus on the Italian Marche region.

Epidemiology of cutaneous T-cell lymphomas: state of the art and a focus on the Italian Marche region.

Journal: European journal of dermatology : EJD

Published: October 12, 2023

A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases.

A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases.

Journal: Current hematologic malignancy reports

Published: June 06, 2023

Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications.

Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications.

Journal: International journal of molecular sciences

Published: March 28, 2022

Prognosis in early stage cutaneous T-cell lymphoma treated with psoralen plus ultraviolet A irradiation and low-dose interferon-α: Long-term efficacy and survival according to conventional and emerging clinical endpoints.

Prognosis in early stage cutaneous T-cell lymphoma treated with psoralen plus ultraviolet A irradiation and low-dose interferon-α: Long-term efficacy and survival according to conventional and emerging clinical endpoints.

Journal: Dermatologic therapy

Published: March 15, 2022

Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report.

Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report.

Journal: Leukemia research reports

Published: March 10, 2021

Showing 1-10 of 10

Last Updated: 09/26/2026